Introduction
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by nonimmune hemolytic anemia, thrombocytopenia and renal impairment. In the last few decades, a series of studies has established that dysregulation of the alternative pathway of complement plays a fundamental role in the pathogenesis of this disease, leading to endothelial damage and systemic thrombotic microangiopathy (TMA). The prognosis of aHUS is poor, with progression to end-stage renal disease (ESRD) or death in half of patients during the first clinical manifestation (1). The risk of post-transplantation recurrence of aHUS depends on the genetic abnormality involved. Patients with complement factor H (CFH) mutations have an estimated recurrence rate of 74%, leading to graft loss in 93% (2) . Consequently, isolated kidney transplantation has been contraindicated in these patients and combined liver-kidney transplantation and pre-emptive plasma exchange (PE) have been used as alternatives. However, both strategies have major limitations. Eculizumab, a humanized monoclonal antibody against terminal complement component 5 (C5), has recently been approved for the treatment of aHUS. Recent successful experiences of its prophylactic use in renal transplantation have been reported (one living nonrelated donor and eight deceased donor transplantations) (3).
We report an adult patient with aHUS-ESRD with a CFH mutation who received prophylactic eculizumab therapy prior to living-related kidney transplantation.
CASE REPORT
A 24-year-old woman was diagnosed of aHUS in April 2008. PE and corticosteroids were used with no improvement in kidney function, and renal replacement therapy with hemodialysis was initiated 1 month later.
A comprehensive complement profile and genetic study of the alternative complement pathway in this patient revealed a c.3497C>T (p.Pro1166Leu) heterozygous mutation in the Cterminus (Short consensus repeat [SCR] 20) of CFH. No mutations were identified in the genes encoding CFI and MCP. C3 levels were low, with normal complement component 4 (C4), CFH and CFI levels. MCP levels in lymphocytes were also normal. Anti-CFH autoantibodies were not detected and ADAMTS-13 activity was normal (90% In September 2011, the patient received a living-related donor kidney transplant. An initial dose of eculizumab (900 mg) was given 1 week before the intervention. During surgery, a further dose of 1200 mg was administered. Eculizumab therapy was continued at a weekly dosage of 900 mg for 4 weeks (the first dose on the day after the procedure). In the fifth week, the dose and interval were increased to 1200 mg of eculizumab every 2 weeks. Two weeks before the start of eculizumab therapy, the patient was vaccinated with a tetravalent meningococcal polysaccharide vaccine (Menveo®). She also received prophylactic antibiotic during the first post-transplant month.
Immunosuppressive treatment consisted of a calcineurin inhibitor (CNI)-free protocol with mycophenolate mofetil (2 weeks before the transplant started with 500 mg twice a day and after the surgery the dose was increased to 1000 mg twice a day), steroids and sirolimus (began on the third day post-transplantation with a dose of 6 mg for 3 days and then adjusted to achieve a target of 8-10 ng/mL during the first year, thereafter 5-8 ng/mL), including induction therapy with antithymocyte globulin (four doses). Three protocol biopsies were performed, at 2 weeks, 3 and 12 months after surgery. All of them showed minimal chronic vascular changes, with no signs of rejection or disease activity. 
DISCUSSION
In the present case, we report a successfully living-related kidney transplantation in an adult patient with ESRD caused by aHUS who received prophylactic eculizumab therapy. Both historically and in recent reviews (4-5), living-related donor renal transplantation has been contraindicated in patients with aHUS associated with mutations in CFH, CFI, C3 and CFB, given the unacceptable risk of disease recurrence, graft loss (6) the donor (7). Nevertheless, progress in the field of genetic studies and the introduction of eculizumab may allow living-related donation in selected cases of aHUS.
Concerning the risk posed by the donor, living-related donor kidney transplantation should only be considered after a thorough molecular and genetic study of the alternative complement pathway, and only if aHUS mutations are identified in the recipient and are not present in the donor. Consequently, we performed a complete complement profile and genetic evaluation in the patient and potential donors, which showed that the mother carried the same CFH mutation as the patient, while the results of the father's study were completely normal. Therefore, the father was chosen as a suitable living kidney donor.
Because of the high recurrence rate of aHUS after kidney transplantation in patients with CFH mutations (2) and the history of PE resistance during the primary disease in our patient, kidney transplantation alone was contraindicated. Liver-kidney transplantation combined with PE has been successfully performed in patients with aHUS and CFH mutation (8), but we excluded this alternative due to the complexity of the surgery and the high associated morbidity and mortality. Eculizumab is a humanized monoclonal antibody against terminal complement protein C5, inhibiting its cleavage in C5a (prothrombotic and proinflamatory peptide) and C5b, preventing the generation of the membrane attack complex (C5b-C9), which causes the endothelial damage that leads to TMA in aHUS patients. The results of clinical trials (9-10) and nine successful previous kidney transplantations (eight deceased donor and one living nonrelated donor) using prophylactic eculizumab (four in combination with PE and five alone) (3, (11) (12) (13) (14) , suggested that prophylactic administration of eculizumab might ensure safe and successful kidney transplantation (avoiding aHUS recurrence).
Living donation allowed starting prophylactic treatment (900 mg) in our patient one week prior to transplantation, ensuring complete blockage of complement before surgery. The second dose (1200 mg), administered during the intervention covered the ischemia-reperfusion injury phase II prospective trials in adult and adolescent aHUS patients (9-10) (900 mg weekly for 4 weeks, increasing the dose and interval to 1200 mg of eculizumab every 2 weeks in the fifth week). No clinical and/or biochemical signs of aHUS relapse have been observed in the first fifteen months. At present, the optimal duration of treatment with eculizumab in aHUS patients remains unknown. After more than 12-month aHUS recurrence-free period, an attempt to taper anti-C5 prophylactic therapy might be a reasonable strategy in our patient. However, should be closely monitored -because she carries a high risk recurrence mutation -and reintroduce the treatment early in case of recurrence. In this regard, prospective clinical trials are crucialto determine the duration of treatment in relation to the genetic profile and history of recurrence in patients with aHUS. Likewise these studies should demonstrate the benefit of prophylactic therapy in patients at high or moderate risk of recurrence and the appropriate duration of this strategy.
Accurate diagnosis of aHUS with all the genetic and molecular analyses is essential to define the best prophylactic strategy in these patients. The presence of gene mutations In summary, the use of prophylactic eculizumab (without PE) could ensure safe and successful kidney transplantation in adult patients with a high risk of aHUS recurrence. When supported by a thorough molecular and genetic study of the alternative complement pathway, living-related donation could be a useful and effective option in selected patients with aHUS.
Further experiences and prospective studies are needed to define the best prophylactic treatment schedule and its duration inkidney transplantation in aHUS-ESRD patients. Plateletcount, lactate dehydrogenase (LDH) and haptoglobin levels remained stable and within the normal range throughout the follow-up. We also measured the pharmacokinetics of
